Company Profile

Sensera Inc (AKA: Triton Systems Co)
Profile last edited on: 5/13/2024      CAGE: 1T3S2      UEI: ----------

Business Identifier: Highly sensitive and accurate immunoassay capabilites supporting medical diagnostics for early intervention
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

200 Turnpike Road
Chelmsford, MA 01824
   (978) 606-2600
Location: Single
Congr. District: 03
County: Middlesex

Public Profile

A spin-off from Triton Systems (a longtime SBIR active firm), Sensera, Inc. is a development stage biological sensor company organized around products for the Point of Care (POC) clinical diagnostics market. The firm went Public on the Australian Stock Exchange in December 2016. Offering ER-A, a POC early and rapid analyzer for the early diagnosis of myocardial injury, ER-A includes a consumable sensor cartridge; and a reader device that measures the signal from the immunoassay, as well as transmits it visually, in print, or through wireless connectivity to the emergency clinical personnel. The driving force for the firm is development of cutting edge inexpensive sensors that detect the presence of chemicals, proteins and bio-organisms. Markets for the firm's sensors are in clinical diagnostics, drug discovery, and home test kits. The firm's sensors are based on conductive polymers and operate in real time with high sensitivity. The Company has a unique sensor array technology that allows rapid, highly sensitive detection of proteins and DNA sequences. The technology is protected by four patents and features femtomolar sensitivity, allowing it to detect proteins like cardiac markers at a concentration at least an order of magnitude lower than current state-of-the-art assays. Sensera is incorporating this technology into a Point of Care (POC) Early & Rapid Analyzer (ER-A) to address unmet needs in the field of emergency medicine. Sensera is positioning the (ER-A ) to initially address one rapidly growing market: Early Diagnosis of Myocardial Injury. ER-A’s high sensitivity for myocardial infarction indicators will enable the diagnosis of heart attacks (acute myocardial infarction or AMI) within two hours of the onset of chest pain, much earlier than possible with current tests. This eliminates the need for emergency personnel to wait for 6 hours in order to treat life-threatening AMI.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
ASX- Austr : SE1
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 2 CBD $849,852
Project Title: Improved Filters for Chemical Warfare Agent Detectors
2003 2 Army $849,999
Project Title: Fluorescent Coated Filters for the Detection of Biological Warfare Agents in Water
2003 1 CBD $69,999
Project Title: Chemical and Biological Sensors with Synthetic Recognition Sites
2003 1 Navy $69,991
Project Title: Personal Multi Analyte Sensor Badge for Toxic Industrial Chemicals
2003 1 Navy $69,993
Project Title: Enhancing Biosensor Life Using Dendrimers

Key People / Management

  Hamed Borhanian -- President

  Samuel Straface -- Acting CEO

  Mark Lebel

  Bijan Radmard

  Jack Salerno -- Founder